As of December 31, 2024, the company had cash, cash equivalents, restricted cash and short-term investments of $357.2M which the company expects to be sufficient to fund operations for the next 12 months and beyond.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- Pliant Therapeutics options imply 29.4% move in share price post-earnings
- Pliant Therapeutics downgraded at Stifel after bexotegrast study discontinued
- Pliant Therapeutics downgraded to Hold from Buy at Stifel
- Leerink downgrades Pliant Therapeutics after trial discontinuation
- Pliant Therapeutics downgraded to Market Perform from Outperform at Leerink